Artiva Biotherapeutics (ARTV) Projected to Post Quarterly Earnings on Thursday

Key Points

• Artiva Biotherapeutics is set to announce its Q2 2025 earnings on August 7th, with analysts expecting a loss of ($0.77) per share.
• The company’s previous earnings report showed a loss of ($0.83) per share, which was below the consensus estimate of ($0.68).
• Six analysts currently rate Artiva Biotherapeutics as a buy, with an average price target of $17.80.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) is expected to announce its Q2 2025 earnings results on Thursday, August 7th. Analysts expect the company to announce earnings of ($0.77) per share for the quarter.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.15). On average, analysts expect Artiva Biotherapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Artiva Biotherapeutics Price Performance

ARTV traded down $0.17 during trading hours on Friday, hitting $2.83. 86,600 shares of the company's stock were exchanged, compared to its average volume of 261,563. Artiva Biotherapeutics has a 12-month low of $1.47 and a 12-month high of $17.31. The firm has a 50 day moving average of $2.10 and a 200 day moving average of $3.12.

Analysts Set New Price Targets

Several research analysts have commented on ARTV shares. Needham & Company LLC lowered their price target on shares of Artiva Biotherapeutics from $23.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, May 15th. HC Wainwright upgraded shares of Artiva Biotherapeutics to a "buy" rating and set a $12.00 price target for the company in a research note on Wednesday, June 11th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $17.80.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.